Signals, Powered By EquityPandit
Novartis Healthcare Private Ltd (NHPL) has announced the launch of Scapho 150 mg to treat moderate to severe plaque psoriasis in adult patients.
The company has said in a statement that Scapho or Secukinumab, an injectable medicine, has been approved by the Drug Controller General of India (DCGI).
And added that this approval marks a significant milestone in the treatment of psoriasis providing a new and important first-line biologic treatment option for its patients, who are candidates for systemic therapy.
